{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:57Z","timestamp":1791999477083,"version":"4.4.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:30:23Z","timestamp":1764973823000},"page":"S17-S31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-1922","authenticated-orcid":false,"given":"Sung-Pin","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Okuzumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Shiuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Chih","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hwei","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9707-1929","authenticated-orcid":false,"given":"Cheng-Hsuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Lin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-7573","authenticated-orcid":false,"given":"Chin-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2025.12.005_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of parkinson's disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.jfma.2025.12.005_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib5","first-page":"879","article-title":"Aggregation of alpha-synuclein in lewy bodies of sporadic parkinson's disease and dementia with lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","article-title":"Protein transmission in neurodegenerative disease","volume":"16","author":"Peng","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in parkinson's disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of parkinson's disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"Hoglinger","year":"2024","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early parkinson's disease: parkinson's progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord"},{"issue":"19","key":"10.1016\/j.jfma.2025.12.005_bib13","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","article-title":"Longitudinal CSF biomarkers in patients with early parkinson disease and healthy controls","volume":"89","author":"Mollenhauer","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in parkinson's disease","volume":"31","author":"Hall","year":"2016","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"alpha-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal Fluid-A systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain"},{"issue":"20","key":"10.1016\/j.jfma.2025.12.005_bib17","doi-asserted-by":"crossref","first-page":"e2513","DOI":"10.1212\/WNL.0000000000011935","article-title":"In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC","volume":"96","author":"Donadio","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00330-020-07240-7","article-title":"Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with parkinson's disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib20","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/brain\/awae142","article-title":"Parkinson's disease variant detection and disclosure: PD GENEration, a North American study","volume":"147","author":"Cook","year":"2024","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","article-title":"Signaling pathways in parkinson's disease: molecular mechanisms and therapeutic interventions","volume":"8","author":"Dong-Chen","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of parkinson's disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1474-4422(24)00378-8","article-title":"Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic","volume":"23","author":"Lim","year":"2024","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/mds.27527","article-title":"Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review","volume":"33","author":"Trinh","year":"2018","journal-title":"Mov Disord"},{"issue":"R1","key":"10.1016\/j.jfma.2025.12.005_bib26","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","article-title":"Parkinson's disease: from monogenic forms to genetic susceptibility factors","volume":"18","author":"Lesage","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jfma.2025.12.005_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.648588","article-title":"Genotype-Phenotype correlations in monogenic parkinson disease: a review on clinical and molecular findings","volume":"12","author":"Guadagnolo","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jfma.2025.12.005_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1023574","article-title":"Genetic architecture of Parkinson's disease subtypes - review of the literature","volume":"14","author":"Dulski","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41531-025-00881-9","article-title":"Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson s disease","volume":"11","author":"Kruger","year":"2025","journal-title":"npj Parkinson's Dis"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/genes12071006","article-title":"The genetics of Parkinson's Disease and implications for clinical practice","volume":"12","author":"Day","year":"2021","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","article-title":"Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study","volume":"22","author":"Rizig","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.parkreldis.2006.12.001","article-title":"Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia","volume":"13","author":"Farrer","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Vilarino-Guell","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12883-017-0972-5","article-title":"Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41588-024-01787-7","article-title":"Systematic rare variant analyses identify RAB32 as a susceptibility gene for familial Parkinson's disease","volume":"56","author":"Hop","year":"2024","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","article-title":"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","volume":"23","author":"Gustavsson","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2025.12.005_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107100","article-title":"Early onset parkinsonism: differential diagnosis and what not to miss","volume":"129","author":"Mohamed Ibrahim","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jnc.14902","article-title":"Are genetic and idiopathic forms of parkinson's disease the same disease?","volume":"152","author":"Correia Guedes","year":"2020","journal-title":"J Neurochem"},{"issue":"6676","key":"10.1016\/j.jfma.2025.12.005_bib40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/mds.27352","article-title":"Genotype-phenotype relations for the Parkinson's disease genes parkin, PINK1, DJ1: MDSGene systematic review","volume":"33","author":"Kasten","year":"2018","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00702-024-02747-5","article-title":"Pathogenesis of Parkinson's disease: from hints from monogenic familial PD to biomarkers","volume":"131","author":"Hattori","year":"2024","journal-title":"J Neural Transm"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib43","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/mds.25132","article-title":"Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease","volume":"27","author":"Kilarski","year":"2012","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib44","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/mds.29610","article-title":"Long-read sequencing resolves a complex structural variant in PRKN Parkinson's disease","volume":"38","author":"Daida","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41531-025-01076-y","article-title":"Large-scale copy number variant analysis in genes linked to Parkinson s disease","volume":"11","author":"Landoulsi","year":"2025","journal-title":"npj Parkinson's Dis"},{"issue":"5674","key":"10.1016\/j.jfma.2025.12.005_bib46","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson's disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib47","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awaa167","article-title":"The role of genetics in Parkinson's disease: a large cohort study in Chinese mainland population","volume":"143","author":"Zhao","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.21415","article-title":"Characterization of PLA2G6 as a locus for dystonia-parkinsonism","volume":"65","author":"Paisan-Ruiz","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.28807","article-title":"Dissecting the phenotype and genotype of PLA2G6-Related parkinsonism","volume":"37","author":"Magrinelli","year":"2022","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib50","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/brain\/awac326","article-title":"PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability","volume":"146","author":"Fevga","year":"2023","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","article-title":"Molecular genetics of Parkinson's disease: contributions and global trends","volume":"68","author":"Funayama","year":"2023","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1474-4422(14)70266-2","article-title":"CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study","volume":"14","author":"Funayama","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib53","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/brain\/awaa064","article-title":"Variants in saposin D domain of prosaposin gene linked to Parkinson's disease","volume":"143","author":"Oji","year":"2020","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib54","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1093\/brain\/awaa279","article-title":"Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy","volume":"143","author":"Lin","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib55","first-page":"226","article-title":"Genome-wide association study of Parkinson's disease in east Asians","volume":"26","author":"Foo","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib56","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib57","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of risk loci for parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study","volume":"77","author":"Foo","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.26153","article-title":"Characterizing the genetic architecture of parkinson's disease in latinos","volume":"90","author":"Loesch","year":"2021","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib59","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","article-title":"Multi-ancestry genome-wide association meta-analysis of Parkinson's disease","volume":"56","author":"Kim","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2025.12.005_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s43587-024-00760-7","article-title":"Exome sequencing in Asian populations identifies low-frequency and rare coding variation influencing Parkinson's disease risk","author":"Chew","year":"2024","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41531-023-00580-3","article-title":"Ethnicity- and sex-specific genome wide association study on Parkinson's disease","volume":"9","author":"Park","year":"2023","journal-title":"npj Parkinson's Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/mds.28494","article-title":"GP2: the Global parkinson's genetics program","volume":"36","year":"2021","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2025.12.005_bib64","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","article-title":"Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?","volume":"20","author":"Mollenhauer","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.parkreldis.2015.02.010","article-title":"Biomarkers of cognitive decline in Parkinson's disease","volume":"21","author":"Lin","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib66","article-title":"Cerebrospinal fluid biomarkers of NLRP3 pathway, immune dysregulation, and neurodegeneration in Parkinson's disease: a meta-analysis","author":"Marinescu","year":"2025","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00415-025-13051-x","article-title":"Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis","volume":"272","author":"Kou","year":"2025","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib68","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of parkinson disease by detection of alpha-Synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using alpha-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib71","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/mds.28715","article-title":"Seed amplification assay to diagnose early parkinson's and predict dopaminergic deficit progression","volume":"36","author":"Concha-Marambio","year":"2021","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease","volume":"34","author":"Kang","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib74","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/mds.28242","article-title":"Blinded RT-QuIC analysis of alpha-Synuclein biomarker in skin tissue from Parkinson's disease patients","volume":"35","author":"Manne","year":"2020","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib75","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"},{"issue":"47","key":"10.1016\/j.jfma.2025.12.005_bib76","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1021\/acs.nanolett.4c03768","article-title":"Blood-based nanoparticle-enhanced quaking-induced conversion (Nano-QuIC): inhibitor-resistant detection of seeding activity in patients diagnosed with Parkinson's disease","volume":"24","author":"Christenson","year":"2024","journal-title":"Nano Lett"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib77","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded alpha-Synuclein in blood years before the diagnosis of Parkinson's disease","volume":"39","author":"Kluge","year":"2024","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib78","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions","volume":"15","author":"Zarkali","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib79","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nano.202200219","article-title":"A comprehensive review on magnetic imaging techniques for biomedical applications","volume":"4","author":"Mukhatov","year":"2023","journal-title":"Nano Select"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jmri.28414","article-title":"Application of neuromelanin MR imaging in parkinson disease","volume":"57","author":"He","year":"2023","journal-title":"J Magn Reson Imag"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282684","article-title":"In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: replication in two cohorts","volume":"18","author":"Hwang","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib82","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.28934","article-title":"Neuromelanin-MRI to quantify and track nigral depigmentation in Parkinson's Disease: a multicenter longitudinal study using template-based standardized analysis","volume":"37","author":"Xing","year":"2022","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib83","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1093\/brain\/awab191","article-title":"The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease","volume":"144","author":"Biondetti","year":"2021","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib84","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.28933","article-title":"Deep learning-based neuromelanin MRI changes of isolated REM sleep behavior disorder","volume":"37","author":"Gaurav","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.26373","article-title":"Motor progression and nigrostriatal neurodegeneration in parkinson disease","volume":"92","author":"Furukawa","year":"2022","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib86","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ene.14009","article-title":"Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?","volume":"26","author":"Okuzumi","year":"2019","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib87","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1212\/WNL.0b013e31829e6fd2","article-title":"Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI","volume":"81","author":"Blazejewska","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib88","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/mds.26932","article-title":"Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease","volume":"32","author":"Mahlknecht","year":"2017","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib89","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1148\/rg.210054","article-title":"Quantitative susceptibility mapping: basic methods and clinical applications","volume":"42","author":"Harada","year":"2022","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s41747-025-00622-w","article-title":"MRI R2\u2217 and quantitative susceptibility mapping in brain tissue with extreme iron overload","volume":"9","author":"Birkl","year":"2025","journal-title":"Eur Radiol Exp"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41531-025-00972-7","article-title":"High-resolution mapping of substantia nigra in Parkinson's disease using 7 tesla magnetic resonance imaging","volume":"11","author":"Madelung","year":"2025","journal-title":"npj Parkinson's Dis"},{"issue":"9","key":"10.1016\/j.jfma.2025.12.005_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162460","article-title":"Quantitative susceptibility mapping in Parkinson's disease","volume":"11","author":"Langkammer","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib93","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mds.27730","article-title":"Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease","volume":"34","author":"Bergsland","year":"2019","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib94","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/mds.29702","article-title":"Longitudinal associations of magnetic susceptibility with clinical severity in Parkinson's disease","volume":"39","author":"Thomas","year":"2024","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.jfma.2025.12.005_bib95","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/mds.27318","article-title":"Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients","volume":"33","author":"Du","year":"2018","journal-title":"Mov Disord"},{"issue":"18","key":"10.1016\/j.jfma.2025.12.005_bib96","doi-asserted-by":"crossref","first-page":"18622","DOI":"10.18632\/aging.103870","article-title":"Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study","volume":"12","author":"Guan","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057904","article-title":"Is R2\u2217 a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up","volume":"8","author":"Ulla","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib98","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/jmri.25723","article-title":"7T: physics, safety, and potential clinical applications","volume":"46","author":"Kraff","year":"2017","journal-title":"J Magn Reson Imag"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib99","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3233\/JPD-191890","article-title":"Substantia Nigra volume dissociates bradykinesia and rigidity from tremor in Parkinson's disease: a 7 tesla imaging study","volume":"10","author":"Poston","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib100","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/mds.29072","article-title":"Locus coeruleus integrity from 7 T MRI relates to apathy and cognition in parkinsonian disorders","volume":"37","author":"Ye","year":"2022","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/jnc.15516","article-title":"The role of neuroimaging in Parkinson's disease","volume":"159","author":"Bidesi","year":"2021","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib102","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/brain\/awad322","article-title":"Neuroinflammation is linked to dementia risk in Parkinson's disease","volume":"147","author":"Kouli","year":"2024","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib103","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib104","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/mds.29186","article-title":"High-contrast imaging of alpha-Synuclein pathologies in living patients with multiple system atrophy","volume":"37","author":"Matsuoka","year":"2022","journal-title":"Mov Disord"},{"issue":"15","key":"10.1016\/j.jfma.2025.12.005_bib105","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","article-title":"Imaging alpha-synuclein pathologies in animal models and patients with Parkinson's and related diseases","volume":"112","author":"Endo","year":"2024","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib106","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/mds.30056","article-title":"Digital outcomes as biomarkers of disease progression in early Parkinson's disease: a systematic review","volume":"40","author":"Rabano-Suarez","year":"2025","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib107","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41746-024-01217-2","article-title":"Digital biomarkers for precision diagnosis and monitoring in Parkinson's disease","volume":"7","author":"Sun","year":"2024","journal-title":"npj Digit Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s42466-025-00426-8","article-title":"Consensus on the clinical utility of digital mobility outcomes for personalized clinical decision support in Parkinson'S disease","volume":"7","author":"Mejia","year":"2025","journal-title":"Neurol Res Pract"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib109","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/1531-8257(200011)15:6<1095::AID-MDS1006>3.0.CO;2-R","article-title":"Visuomotor skill learning on serial reaction time task in patients with early Parkinson's disease","volume":"15","author":"Stefanova","year":"2000","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124140","article-title":"Digital health in Parkinson's Disease and atypical parkinsonism-new frontiers in motor function and physical activity assessment: review","volume":"14","author":"Bacanoiu","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16415","article-title":"Antiparkinsonian medication masks motor signal progression in de novo patients","volume":"9","author":"Brzezicki","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41531-025-00897-1","article-title":"Digital gait biomarkers in Parkinson's disease: susceptibility\/risk, progression, response to exercise, and prognosis","volume":"11","author":"Mancini","year":"2025","journal-title":"npj Parkinson's Dis"},{"issue":"13","key":"10.1016\/j.jfma.2025.12.005_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/s25134071","article-title":"Determining Falls risk in people with Parkinson's disease using wearable sensors: a systematic review","volume":"25","author":"Bradley","year":"2025","journal-title":"Sensors (Basel)"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib114","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41746-024-01144-2","article-title":"Digital biomarkers for non-motor symptoms in Parkinson's disease: the state of the art","volume":"7","author":"Janssen Daalen","year":"2024","journal-title":"npj Digit Med"},{"key":"10.1016\/j.jfma.2025.12.005_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1652378","article-title":"Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson's disease","volume":"16","author":"Guo","year":"2025","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib116","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"20","key":"10.1016\/j.jfma.2025.12.005_bib117","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in Early parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"Pt 10","key":"10.1016\/j.jfma.2025.12.005_bib118","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson's disease: insights into motor complications from Sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib119","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.jfma.2025.12.005_bib120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.514","volume":"55","author":"Hsu","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2025.12.005_bib121","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/PL00007731","article-title":"Sleep disorders in Parkinson's disease","volume":"245","author":"Stocchi","year":"1998","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.12.005_bib122","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"issue":"20","key":"10.1016\/j.jfma.2025.12.005_bib123","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jfma.2025.12.005_bib124","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","article-title":"Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa","volume":"22","author":"Hauser","year":"2007","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib127","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jfma.2025.12.005_bib128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.sleep.2016.01.016","article-title":"Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study","volume":"21","author":"Pierantozzi","year":"2016","journal-title":"Sleep Med"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/mds.22343","article-title":"Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","article-title":"Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study","volume":"110","author":"Fenelon","year":"2003","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib132","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","article-title":"Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations","volume":"111","author":"Reichmann","year":"2005","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib134","first-page":"1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Nomecomt Study Group Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib135","first-page":"747","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","year":"1997","journal-title":"Parkinson Study Group Ann Neurol"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib136","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib137","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"Ferreira","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib138","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Lees","year":"2017","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib139","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson's disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib142","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"Hattori","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib143","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib144","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib145","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in parkinson disease (EASE LID Study): a randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"issue":"23","key":"10.1016\/j.jfma.2025.12.005_bib146","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","article-title":"A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease","volume":"70","author":"Stacy","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib147","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \"off\" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib148","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study","volume":"25","author":"Mizuno","year":"2010","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib149","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jfma.2025.12.005_bib150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib151","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1097\/MJT.0000000000001707","article-title":"Levodopa-Carbidopa-entacapone intestinal gel in advanced parkinson disease: a multicenter real-life experience","volume":"31","author":"Szasz","year":"2024","journal-title":"Am J Therapeut"},{"issue":"9","key":"10.1016\/j.jfma.2025.12.005_bib152","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.12.005_bib153","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2025.12.005_bib154","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41531-018-0069-x","article-title":"Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort","volume":"4","author":"Eusebi","year":"2018","journal-title":"npj Parkinson's Dis"},{"issue":"23","key":"10.1016\/j.jfma.2025.12.005_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233736","article-title":"Levodopa-Induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib156","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40263-024-01087-y","article-title":"Impulse control disorders in Parkinson's disease: an overview of risk factors, pathogenesis and pharmacological management","volume":"38","author":"Carbone","year":"2024","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib157","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14656566.2018.1445721","article-title":"Pharmacological interventions for psychosis in Parkinson's disease patients","volume":"19","author":"Friedman","year":"2018","journal-title":"Expet Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib158","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/mds.30162","article-title":"Update on treatments for Parkinson's disease motor fluctuations \u2013 an international parkinson and movement disorder society evidence\u2010based medicine review","volume":"40","author":"De Bie","year":"2025","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib159","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International parkinson and movement disorder society evidence\u2010based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib160","series-title":"Clinical practice guideline","article-title":"Parkinson's disease in adults","author":"Care","year":"2017"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib161","first-page":"145","article-title":"Evidence-Based Taiwan consensus recommendations for the treatment of Parkinson's disease","volume":"32","year":"2023","journal-title":"Acta Neurol Taiwan"},{"issue":"36","key":"10.1016\/j.jfma.2025.12.005_bib162","doi-asserted-by":"crossref","first-page":"E989","DOI":"10.1503\/cmaj.181504","article-title":"Canadian guideline for Parkinson disease","volume":"191","author":"Grimes","year":"2019","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib163","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib164","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/mds.30162","article-title":"Update on treatments for Parkinson's disease motor fluctuations - an international parkinson and movement disorder society evidence-based medicine review","volume":"40","author":"de Bie","year":"2025","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jfma.2025.12.005_bib165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/neuros\/nyy037","article-title":"Congress of neurological surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary","volume":"82","author":"Rughani","year":"2018","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib166","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1172\/JCI46482","article-title":"Modulation of subthalamic T-type Ca(2+) channels remedies locomotor deficits in a rat model of Parkinson disease","volume":"121","author":"Tai","year":"2011","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib167","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ana.23618","article-title":"Subthalamic discharges as a causal determinant of parkinsonian motor deficits","volume":"72","author":"Tai","year":"2012","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.jfma.2025.12.005_bib168","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/mds.29052","article-title":"How does deep brain stimulation change the course of Parkinson's disease?","volume":"37","author":"Mahlknecht","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib169","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clinph.2024.05.007","article-title":"Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter","volume":"164","author":"Lefaucheur","year":"2024","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","article-title":"Long-term outcomes of deep brain stimulation in Parkinson disease","volume":"15","author":"Limousin","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib171","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/mds.27096","article-title":"Directional leads for deep brain stimulation: opportunities and challenges","volume":"32","author":"Schupbach","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib172","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.2781","article-title":"Long-term personalized adaptive deep brain stimulation in parkinson disease: a nonrandomized clinical trial","author":"Bronte-Stewart","year":"2025","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib173","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41531-024-00843-7","article-title":"MRgFUS subthalamotomy in Parkinson's disease: an approach aimed at minimizing lesion volume","volume":"10","author":"Campins-Romeu","year":"2024","journal-title":"npj Parkinson's Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.12.005_bib174","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.1542","article-title":"Invasive and noninvasive brain stimulation in Parkinson's disease: clinical effects and future perspectives","volume":"106","author":"Chen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jfma.2025.12.005_bib175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neucli.2020.05.002","article-title":"Transcranial magnetic stimulation and gait disturbances in Parkinson's disease: a systematic review","volume":"50","author":"Nardone","year":"2020","journal-title":"Neurophysiol Clin"},{"issue":"5","key":"10.1016\/j.jfma.2025.12.005_bib176","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/mdc3.13228","article-title":"Combining device-aided therapies in Parkinson's disease: a case series and a literature review","volume":"8","author":"Boura","year":"2021","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib177","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41531-024-00738-7","article-title":"A skin-specific alpha-Synuclein seeding amplification assay for diagnosing Parkinson's disease","volume":"10","author":"Kuang","year":"2024","journal-title":"npj Parkinson's Dis"},{"issue":"10","key":"10.1016\/j.jfma.2025.12.005_bib178","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov Disord"},{"issue":"121","key":"10.1016\/j.jfma.2025.12.005_bib179","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated \u03b1-Synuclein in parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jfma.2025.12.005_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107240","article-title":"A systematic review of biofluid phosphorylated alpha-synuclein in Parkinson's disease","volume":"132","author":"Pedersen","year":"2025","journal-title":"Parkinsonism & related disorders"},{"key":"10.1016\/j.jfma.2025.12.005_bib181","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.jfma.2025.12.005_bib182","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated alpha-Synuclein in patients with synucleinopathies","volume":"331","author":"Gibbons","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib183","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41531-024-00631-3","article-title":"Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson's disease","volume":"10","author":"Lakhani","year":"2024","journal-title":"npj Parkinson's Dis"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib184","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40035-025-00495-4","article-title":"Dorsal hyperintensity and iron deposition patterns in the substantia nigra of Parkinson's disease, idiopathic REM sleep behavior disorder, and Parkinson-plus syndromes at 7T MRI: a prospective diagnostic study","volume":"14","author":"Su","year":"2025","journal-title":"Transl Neurodegener"},{"issue":"11","key":"10.1016\/j.jfma.2025.12.005_bib185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025533","article-title":"Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients","volume":"8","author":"Xu","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jfma.2025.12.005_bib186","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.28814","article-title":"Glia imaging differentiates multiple System atrophy from Parkinson's disease: a positron emission tomography study with [(11) C]PBR28 and machine learning analysis","volume":"37","author":"Jucaite","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.jfma.2025.12.005_bib187","series-title":"Levodopa\/carbidopa\/entacapone intestinal gel \u2013 product information","year":"2022"},{"key":"10.1016\/j.jfma.2025.12.005_bib188","series-title":"Piribedil \u2014 list of nationally authorised medicinal products (European Medicines Agency PSUSA\/00002436\/202303)","year":"2023"},{"key":"10.1016\/j.jfma.2025.12.005_bib189","article-title":"Trihexyphenidyl hydrochloride 2 mg tablets \u2013 summary of product characteristics","author":"Accord","year":"2022","journal-title":"Electronic Medicines Compendium (eMC), United Kingdom"},{"key":"10.1016\/j.jfma.2025.12.005_bib190","article-title":"Biperiden hydrochloride 2 mg tablets V summary of product characteristics (oral)","author":"Health Products Regulatory Authority","year":"2020","journal-title":"Health Products Regulatory Authority (HPRA)"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625006497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625006497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:47:16Z","timestamp":1785876436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625006497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":190,"alternative-id":["S0929664625006497"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.12.005","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}